Search for a command to run...
Ipca Laboratories Ltd. shows moderate growth and profitability compared to its peers in the Pharmaceuticals & Drugs sector. The company holds a relatively high PE ratio, indicating potential overvaluation, while other peers demonstrate stronger profitability metrics and lower debt levels, suggesting a broader concern in the sector.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
IPCALAB | ₹1,365.85 | ₹34,652.16Cr | 53.25 | 13.10% | 0.22 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |